Clinical Trial Update: Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ADX-038 for complement-mediated kidney disease, including IgA nephropathy and C3 glomerulopathy, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Iga Nephropathy

Drugs mentioned

• ADX-038

Snippet

Sponsor: ADARx Pharmaceuticals, Inc. | Conditions: IgAN, C3G | Phase 2 | Status: RECRUITING